14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We evaluated the population pharmacokinetics (PPK) and exposure-response relationship of imatinib mesylate in Iranian patients with chronic myeloid leukemia (CML).This study was designed to assess steady state (SS) imatinib trough concentrations (Cmin) and pharmacokinetics parameters of imatinib in patients with CML in chronic phase after at least 12-month treatment.

          Related collections

          Author and article information

          Journal
          Cancer Chemother Pharmacol
          Cancer chemotherapy and pharmacology
          Springer Science and Business Media LLC
          1432-0843
          0344-5704
          Jul 2014
          : 74
          : 1
          Affiliations
          [1 ] Biopharmaceutics and Pharmacokinetic Division, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, 14155-651, Tehran, Iran.
          Article
          10.1007/s00280-014-2473-1
          24817601
          61cddebb-8198-4ea7-979c-a6645789de1f
          History

          Comments

          Comment on this article